Alignment Healthcare, Inc. ALHC
We take great care to ensure that the data presented and summarized in this overview for Alignment Healthcare, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALHC
View all-
General Atlantic LLC New York, NY61MShares$735 Million20.6% of portfolio
-
Warburg Pincus LLC New York, NY13.6MShares$164 Million8.97% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY10.9MShares$131 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.65MShares$116 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.19MShares$98.7 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.59MShares$67.4 Million0.04% of portfolio
-
Durable Capital Partners LP Bethesda, MD5.48MShares$66 Million0.49% of portfolio
-
Wellington Management Group LLP Boston, MA4.18MShares$50.4 Million0.01% of portfolio
-
Hood River Capital Management LLC Palm Beach Gardens, FL3.55MShares$42.8 Million0.78% of portfolio
-
8 Knots Management, LLC Dallas, TX2.45MShares$29.5 Million3.94% of portfolio
Latest Institutional Activity in ALHC
Top Purchases
Top Sells
About ALHC
Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in the states of California, North Carolina, and Nevada. It also coordinates and provides covered health care services, including professional, institutional, and ancillary services to members enrolled in certain benefit plans of unaffiliated Medicare Advantage Health Maintenance Organizations. The company was founded in 2013 and is based in Orange, California.
Insider Transactions at ALHC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 15
2024
|
Dawn Christine Maroney President, Markets |
SELL
Open market or private sale
|
Direct |
30,000
-1.74%
|
$330,000
$11.35 P/Share
|
Nov 11
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
30,500
-24.71%
|
$396,500
$13.42 P/Share
|
Nov 11
2024
|
Joseph S Konowiecki Director |
SELL
Open market or private sale
|
Direct |
6,920
-0.61%
|
$89,960
$13.73 P/Share
|
Nov 11
2024
|
John E Kao Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
90,000
-3.54%
|
$1,170,000
$13.42 P/Share
|
Nov 04
2024
|
Hakan Kardes Chief Experience Officer |
SELL
Open market or private sale
|
Direct |
20,500
-5.45%
|
$266,500
$13.06 P/Share
|
Nov 01
2024
|
Hakan Kardes Chief Experience Officer |
SELL
Open market or private sale
|
Direct |
4,500
-1.18%
|
$54,000
$12.98 P/Share
|
Oct 31
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
36,197
-22.68%
|
$434,364
$12.04 P/Share
|
Oct 29
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
4,483
-2.73%
|
$53,796
$12.01 P/Share
|
Oct 15
2024
|
Dawn Christine Maroney President, Markets |
SELL
Open market or private sale
|
Direct |
30,000
-1.71%
|
$300,000
$10.77 P/Share
|
Oct 14
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
30,500
-15.67%
|
$335,500
$11.5 P/Share
|
Oct 09
2024
|
John E Kao Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
90,000
-3.42%
|
$990,000
$11.33 P/Share
|
Oct 08
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
39,320
-16.81%
|
$471,840
$12.04 P/Share
|
Oct 08
2024
|
Hyong Kim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
22,460
-4.04%
|
$247,060
$11.03 P/Share
|
Oct 02
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
9,125
-3.75%
|
$100,375
$11.01 P/Share
|
Oct 01
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
21,375
-4.13%
|
$213,750
$10.75 P/Share
|
Oct 01
2024
|
Christopher J Joyce Chief Legal and Admin. Officer |
SELL
Open market or private sale
|
Direct |
667
-0.18%
|
$7,337
$11.79 P/Share
|
Sep 17
2024
|
Joseph S Konowiecki Director |
SELL
Open market or private sale
|
Direct |
16,413
-1.42%
|
$180,543
$11.77 P/Share
|
Sep 16
2024
|
Dawn Christine Maroney President, Markets |
SELL
Open market or private sale
|
Direct |
30,000
-1.68%
|
$330,000
$11.7 P/Share
|
Sep 16
2024
|
John E Kao Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
90,000
-3.31%
|
$990,000
$11.7 P/Share
|
Sep 13
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
14,500
-5.2%
|
$174,000
$12.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 2.37M shares |
---|---|
Open market or private purchase | 103K shares |
Open market or private sale | 1.47M shares |
---|---|
Payment of exercise price or tax liability | 34.5K shares |
Bona fide gift | 6K shares |